Penn Transplant Institute

Lung Transplant Research and Clinical Trials

More people are surviving end-stage organ disease than ever before. Over the last decade, many people with lung disease have witnessed the success of research studies that have helped improve and increase treatment options.

As an experienced transplant center in an academic setting, Penn Transplant Institute is committed to finding new and better treatments for transplant patients.

Lung transplant research at Penn Medicine focuses on novel therapeutics and immunosuppression strategies for advanced lung disease with programs dedicated to interstitial lung disease, adult cystic fibrosis, pulmonary vascular disease and management of COPD. A minimally invasive surgical approach to lung transplant is standard practice at Penn. See below for lung transplant clinical trials conducted at Penn.

Clinical Risk Factors of Primary Graft Failure, a Multicenter Study
Genetics of Primary Graft Failure, a Multicenter Study
Clinical Trials in Organ Transplantation
The association of anti-Col (V) antibodies with development of Primary Graft Dysfunction following lung transplantation
Regulatory T Cells and Primary Graft Failure
Innate Immunity and lung transplantation
Prospective Registry of Outcomes in Patients Electing Lung Transplantation (PROPEL): A correlative analysis using gene signature array
NOVEL Lung Trial: Normothermic Ex Vivo Lung Perfusion (EVLP) as an Assessment of Extended/Marginal Donor Lungs
A Multi-center, Multinational, Retrospective Review of Voriconazole Experience for the Prophylaxis against Invasive Aspergillosis in Lung Transplant Recipients

Advanced Lung Disease Research Studies


A Phase 3, Double-Blind, Multicenter, Randomized, Placebo-Controlled Trial Evaluating Repeated Courses of Aztreonam for Inhalation Solution in Subjects with non-CF Bronchiectasis and Gram-Negative Endobronchial Infection (AIR-BX1), Gilead
A Consolidated Database of Non-Cystic Fibrosis Bronchiectasis Patients from Major Clinical and Research Institutions (NON-TREATMENT)
Nontuberculous Mycobacterial Lung Disease (NTM): A randomized, double-blind, placebo-controlled study of Liposomal Amicakcin for inhalation (Arikace) in patients with recalcitrant nontuberculous mycobacterial lung disease
Genomic Research in Alpha 1 Anti-trypsin disease and Sarcoidosis


A prospective, longitudinal, non-pharmacologic, case-controlled study to evaluate longitudinal disease behavior and biomarker data over a 52 week period in idiopathic pulmonary fibrosis patients
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Efficacy and Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis, InterMune (TREATMENT)

Pulmonary Hypertension

GRIPHON: Prostacyclin (PGI2) Receptor agonist In Pulmonary arterial Hypertension (TREATMENT): A multicenter, double-blind, placebo-controlled Phase 3 study to demonstrate the efficacy and safety of ACT-293987 in patients with pulmonary arterial hypertension
AIPH: Anastrozole in Patients with Pulmonary Arterial Hypertension (TREATMENT)

Cystic Fibrosis

A randomized, multi-center, open-label, cross over, phase IV study in cystic fibrosis (CF) patients to compare the tolerability, safety and efficacy of tobramycin inhalation powder (TIP) with tobramycin nebulizer solution (TOBI) as assessed by the switch-over of treatments
A prospective, 5-year Registry Study to Monitor the Susceptibility to Aztreonam of Pseudomonas aeruginosa (PA) Isolates from Patients with Cystic Fibrosis in the United States
Cystic Fibrosis Foundation Patient Registry
Continuous Alternating Therapy (CAT) Regimen of Inhaled Antibiotics for the Treatment of Chronic Pulmonary Pseudomonas aeruginosa infection
Cell Mediated Immunity Against the Cystic Fibrosis Transmembrane Conductance Regulator Protein in Patients with Cystic Fibrosis (3 blood draws)
Modulation of inflammation and oxidation biomarkers in cystic fibrosis by a botanical phenolic
  • Investigator: Jason Turowski, MD
Improving the Effectiveness of Pulmozyme at sites of infection by Combination with Multivalent Anions and Acting Depolymerizing Factors
  • Investigator: Paul Jamney, PhD

For more information about clinical trials at the Penn Transplant Institute, see Research & Clinical Trials.